Lenskart Solutions Ltd Q1 FY27 Earnings Call: Product Margin Crosses 70% for First Time, International EBITDA Margin Crosses 10%

Cofacto Research Published August 14, 2026 5 min read

Lenskart Solutions Ltd held its Q1 FY27 earnings call on August 12, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Headline Financial Metrics

  • Rs.2,734 Cr consolidated revenue — grew 34% YoY in Q1 FY 2026-2027, with India at Rs.1,531 Cr (+30.7%) and international at Rs.1,203 Cr (+38% headline, +29% constant currency).
  • Rs.228 Cr PAT — up 182% YoY; compares to ~Rs.530 Cr PAT for the full prior year (FY 2025-2026).
  • Consolidated product margin crossed 70% for the first time, versus ~69% in the prior four quarters (FY 2025-2026).
  • India EBITDA margin (pre-Ind AS 116) expanded 200 bps YoY to 15.4%, with EBITDA of Rs.236 Cr in Q1 FY 2026-2027.
  • International EBITDA margin improved to 10.6% (pre-Ind AS 116) from 4.5% a year ago, with EBITDA of Rs.127 Cr — triple the prior-year quarter.
  • Operating cash flow of Rs.297 Cr represented 82% EBITDA conversion; ROCE improved to 23% from 14% in Q1 FY 2026-2027.

Accelerating Physical Reach and Same-Store Momentum

  • 116 net new stores added in Q1 FY 2026-2027 — 455 net new stores in the trailing nine months (fastest expansion ever) across 140 new towns.
  • Same-store sales growth accelerated to 18% in Q1 FY 2026-2027, up from 16% in Q1 FY 2025-2026; same-pin-code sales grew 24%.
  • Store density rose from 1.5 to 1.6 stores per pin code across 1,517 pin codes, with 150 stores added in existing pin codes in Q1.
  • Addressable gap of ~6,100 unserved pin codes remains; management sees potential for at least 3,000 additional stores in India and a long-term goal of 10,000+ stores in India alone.
  • Volume grew 23% in Q1 FY 2026-2027, driven by eye-test top-of-funnel expansion; management noted conversion may be temporarily impacted as new first-time testers take longer to purchase.

Profitability Inflection and Dual Brand Rollout

  • International revenue grew 38% (29% constant currency) to Rs.1,203 Cr in Q1 FY 2026-2027, with iWear units up 37.6% and transacting customers up 27.8%.
  • International product margin expanded to 77.1% via supply chain integration; EBITDA margin improved to 10.6% (pre-Ind AS 116), crossing the 10% threshold for the first time.
  • Sunglasses units grew 58.4% internationally in the peak Q1 season; core prescription iTests rose 20.5%.
  • Dual brand strategy achieved >25% volume market share in Singapore (period up to Q1 FY 2026-2027), with the same Lenskart + OwnDays approach now applied in Thailand and "working well" per management.
  • Meller tracking to become $70M+ brand (acquired at $35M); the company does not plan a dual brand strategy in Japan, adapting international approach market by market based on learnings.
  • Management noted store acceleration in international markets is approaching but not in FY 2026-2027, as tech integration (remote optometry, self-AI eye test) and geo-analytics (via GIAQ) are being completed to avoid customer experience decline.

Premium Lenses, Branded Partnerships, and Entry-Level Scale

  • Own-brand premium segment (own-days) reached Rs.1,500+ Cr annual prescription sales; high-end Rodenstock and Tokai lines generated ~Rs.250 Cr annually.
  • Premium lens segment (price points above Rs.30,000) achieved a Rs.250 Cr run rate in Q1 FY 2026-2027.
  • Rs.500 entry eyewear (Hustler Club) sold 5,30,000 pairs from one platform in Q1; management confirmed the price point is "more margin accretive" than higher price points.
  • For branded lenses, Lenskart acts as both manufacturing and brand licensing partner — manufacturing in-house using brand-supplied raw materials and design info, or importing directly; the arrangement started in India and is now expanding into international markets.
  • The Rs.500 frame is engineered to avoid cannibalization through an omnichannel journey with face-scan verification and a house-of-brands strategy, per management.

Scaling Eye Tests, Remote Optometry, and Manufacturing Capacity

  • 63 lakh eye tests (iTests) conducted in India in Q1 FY 2026-2027 — up 42.7% YoY; over 1 crore first-time eye tests were conducted in FY 2025-2026.
  • Remote optometry expanded to 786 stores (from 168 at FY 2025-2026 year-end), with process compliance scored via Tango Eye computer vision and post-purchase power change rate tracking.
  • Self-iTest (AI-driven eye exam) piloted in the quarter; B by Lenskart signups reached 80,000+ with a few hundred glasses shipping daily.
  • Hyderabad plant capex of Rs.132 Cr in Q1 FY 2026-2027, with in-house frame manufacturing and backward integration positioned to structurally offset currency headwinds on product margins.
  • Talent and engineering capability cited by management as the biggest constraint for scaling to 10,000 stores; enablers include remote optometry (700+ stores), AI eye-test tools, and RFID deployment.
  • Management noted short-term currency risks remain on product margins despite structural initiatives.

Long-term Potential and Near-term Priorities

  • Management estimates 78 Cr Indians need vision correction today, heading to 94 Cr by FY 2029-2030, framing this as "a market to build, not capture."
  • Potential for 10,000+ stores in India identified by management, with ~6,100 unserved pin codes and densification potential for at least 3,000 additional stores.
  • "Drishti ki Daud" Independence Day campaign launched in FY 2026-2027 — 20,000 steps results in a pair of glasses donated to someone in need; every additional 10,000 steps adds another pair.
  • "Run for Frame" in Thailand drew 40,000 runners in FY 2026-2027; over 5 lakh people ran in India.
  • International store acceleration not expected in FY 2026-2027 as tech integration and geo-analytics are prioritized to avoid customer experience decline.
  • Next quarterly call announced for Q2 FY 2026-2027; IR contact: investor.relations@lenskart.in.
Share on X · LinkedIn · WhatsApp

Disclaimer: This earnings call summary is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.

Powered by Cofacto — AI research platform for Indian stocks, every claim cited from primary filings

Login Now